Sodium 5-(1,5-dimethyl-1H-pyrazol-4-yl)-isoxazole-3-carboxylate
CAS: 1147201-50-0
Ref. 3D-XVB20150
| 1g | To inquire | ||
| 5g | To inquire |
Product Information
Sodium 5-(1,5-dimethyl-1H-pyrazol-4-yl)-isoxazole-3-carboxylate (SNX-111) is a novel, orally active, nonselective inhibitor of the enzyme diacylglycerol acyltransferase 2 (DGAT2). SNX-111 is in development for the treatment of lipid metabolism disorders and as an adjunct to diet and exercise. In a study of patients with hyperlipidaemia and type 2 diabetes mellitus, SNX-111 was found to reduce serum triglycerides and cholesterol levels. SNX-111 also reduced blood sugar levels in diabetic patients with elevated blood sugar levels.
SNX-111 has been shown to be well tolerated in short term clinical trials for up to 12 weeks. The most common side effects were headache, diarrhoea, nausea, vomiting and abdominal pain.
Chemical properties
Technical inquiry about: 3D-XVB20150 Sodium 5-(1,5-dimethyl-1H-pyrazol-4-yl)-isoxazole-3-carboxylate
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.
